Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 47

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 8
Chunk 47
---
453,800 
  
    Total stock-based compensation expense 
    $150,614  
    $444,184  
    $572,268  
    $2,001,727 

As
of September 30, 2025, total compensation cost not yet recognized related to unvested stock options was approximately $0.45 million,
which is expected to be recognized over a weighted-average period of approximately 1.0 years.

The
Company estimates the fair value of stock options on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes
option-pricing model requires estimates of highly subjective assumptions, which affect the fair value of each stock option. The weighted
average inputs used to measure the value of the options granted during the nine months ended September 30, 2025, are presented in the
table below. The weighted average fair value of stock options granted during the nine months ended September 30, 2025 was $8.14 per share.

 SCHEDULE
OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED 

    2025

    Exercise
    price
     
    $
    9.24

    Expected
    term (in years)

    5.5

    Volatility

    128.4
    %
  
    Risk
    free rate

    4.1
    %
  
    Dividend
    yield

    0
    %

    F-9

The
following table presents the exercise price of outstanding stock options as of September 30, 2025:

 SCHEDULE
OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS 

    Exercise price 
    Options  outstanding 

    $0.01 - $80.00 
     55,777 

    $0.01 - $80.00 
     55,777 
  
    $80.01 or higher 
     48,619 
  
    Total 
     104,396 

NOTE
6: CAPITALIZATION

    a.
    As
    of September 30, 2025 and December 31, 2024, the Company had 200,000,000 shares of common stock authorized and 1,641,920 and 428,799
    shares issued and outstanding, respectively. As of September 30, 2025 and December 31, 2024, the Company had